The global leukocyte adhesion deficiency management market is expected to register a valuation of USD 8.09 billion in 2023 and is projected to reach USD 15.2 billion by 2033. Throughout the 2023 to 2033 forecast period, the market is poised to flourish at a CAGR of 6.51%.
Technological advancements and medical science have played a key role in the development of new treatments and therapies for an array of disorders and diseases which augments market growth. Also, government approvals and support and increasing awareness regarding various primary immunodeficiency diseases treatment is propelling the market growth of Leukocyte adhesion deficiency management market.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 8.09 billion |
| Anticipated Forecast Value (2033) | USD 15.2 billion |
| Projected Growth Rate (2023 to 2033) | CAGR 6.51% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for Leukocyte adhesion deficiency treatment was worth USD 6.5 billion in 2018, while growing at a CAGR of 4.47% during the historical period. With the advancements in technology and medical science in the development of new treatments and therapies for an array of disorders and diseases, the market is witnessing various opportunities.
Conventionally, leukocyte adhesion deficiency has been predominantly characterized as per the immunologic phenotype. Research and development activities within the leukocyte adhesion deficiency market are largely focused on the discovery of human genes that could cause leukocyte adhesion deficiency.
Within the primary immunodeficiency landscape, there are four core areas currently being investigated. These include role of follicular T cells in developing antibody responses, role of impaired B-cell maturation in inducing inflammatory conditions, inflammatory and autoimmune manifestations, and recently discovered gene defects.
Furthermore, researchers are exploring the overall efficacy of lentiviral vector-mediated gene therapies in patients suffering from adenosine deaminize-deficient severe combined immunodeficiency (SCID).
Over the past decade, the management of primary immunodeficiency has advanced at a fast pace due to a rise in investments and focus on research. Strides taken by sequencing, gene-editing tools, and the development of new drugs are anticipated to boost prospects of the market for leukocyte adhesion deficiency during the forecast period.
At the back of these factors, the global leukocyte adhesion deficiency is expected to attain a value of USD 15.2 billion by end of the forecast period, while exhibiting a CAGR of 6.51%.
Advancements in Genetic Management and Next-generation Sequencing Technologies to drive Market Growth
The advent of genome sequencing and increased interest in genome studies have played an important role in enhancing and understanding the overall genetics of leukocyte adhesion deficiency. Contemporary research has generated new frontiers for understanding the pathogenesis of common variable primary immunodeficiency.
Recently, the adoption of DNA sequencing, RNA sequencing, epigenetic, and proteomic profiles is growing, to assess common variable primary immunodeficiency including leukocytic adhesion deficiency. Scientists and researchers are increasingly focusing on understanding the genetics of primary immunodeficiency which will help in expanding the market.
Furthermore, the prevalence of primary immunodeficiency is rising, furthering the demand for novel treatments. Credited to several discoveries in monogenic forms of common variable primary immunodeficiency, significant progress in sequencing technologies is triggered.
In the past decade, owing to advancements in technology and research, participants of the primary immunodeficiency market are swaying toward the use of omics-based technologies and integrating next-generation platforms in the leukocyte adhesion deficiency therapeutics which will also help in market expansion in the forecast period.
Principal Consultant
High Cost of Immunotherapy to restrain Industry Growth
Growth of the leukocyte adhesion deficiency therapeutics market is expected to be restrained due to high cost of immunotherapy and side effects of immunodeficiency disease treatments like leukocyte adhesion deficiency treatment.
For instance, according to an article published by ScienceDirect in April 2020, the total cost of immunodeficiency disease treatment is estimated to be around USD 6,500 to USD 108,463 per patient. These factors are anticipated to challenge growth of the market.
North America expected to dominate with the maximum share
North America is anticipated to dominate the market of Leukocyte adhesion deficiency treatment by reaching market valuation of USD 6.1 billion by end of the forecast period. This region is anticipated to account for 40.5% market share by 2033.
The market in United States alone accounted for 29.1% market share in 2022 in this region and is expected to retain its dominance during the projected timeline.
As per FMI, the region is expected to witness credible growth due to an increasing prevalence of immunodeficiency diseases, surging technological advancements in genetics and stem cell therapy, as well as a well-established healthcare infrastructure.
An increasing number of product approvals is also expanding the regional market. In September 2020, Octapharma USA Inc. received the Medicare Part B approval for Cutaquig, a drug used for the treating humoral immunodeficiency in adults and children.
Such approvals from insurance providers are anticipated to encourage people to opt for immunotherapy and thus drive the growth of leukocyte adhesion deficiency treatment market over the forecast period.
Asia-Pacific market expected to reflect fastest CAGR
Leukocyte adhesion deficiency therapeutics market in this region is projected to grow with fastest CAGR of 6.9% during the forecast period. The target industry of China is projected to dominate the market in this region while growing at a CAGR of 6.1% during the forecast period.
Increasing willingness among people to spend on novel therapeutics, rising research and developments in immunotherapy therapeutics, and increasing investments in healthcare sector is propelling market growth in this region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Hematopoietic Stem Cell Transplantation to dominate the market with maximum share
The hematopoietic stem cell transplantation segment is anticipated to witness significant growth owing to the factors such as the increasing prevalence of primary immunodeficiency disease and technological advancement in stem cell therapy. This segment is projected to dominate the market with a market share of around 38% by end of the forecast period.
Stem cell transplantation therapies have a very high success rate. In addition, stem cell reconstitution is a first-line treatment for severe leukocyte adhesion deficiency type I. These benefits provided by this therapy will augment this segment’s growth during the forecast period.
Hospitals will lead the segment with the maximum share
Hospitals are expected to lead the segment with a market share of around 71% by end of the forecast period. The growth is attributable to factors such as rapid adoption of next-generation novel therapeutics, robust infrastructure for various primary immunodeficiency therapeutics and availability of skilled professionals. Furthermore, technological advancements in treatment of Leukocyte adhesion deficiency are also propelling growth of this segment.
The global leukocyte adhesion deficiency management market is characterized by the presence of a large number of players. Some prominent expansion strategies and business expansion activities include partnerships and agreements, initiating clinical trials and raising funding for various business activities.
The major players in the market are: Orpha Labs, Avalo Therapeutics, Inc., Rocket Pharmaceuticals Inc., Sigma-Aldrich, Aspen Neuroscience, Magenta Therapeutics, Rubius Therapeutics, Enochian Biosciences, Sana Biotechnology, Vertex Pharmaceuticals
Some recent developments in the market are:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 8.09 billion |
| Market Value in 2033 | USD 15.2 billion |
| Growth Rate | CAGR of 6.51% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment, End User, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Orpha Labs; Avalo Therapeutics, Inc.; Rocket Pharmaceuticals Inc.; Sigma-Aldrich; Aspen Neuroscience; Magenta Therapeutics; Rubius Therapeutics; Enochian Biosciences; Sana Biotechnology; Vertex Pharmaceuticals |
| Customization | Available Upon Request |
In 2023, the market is valued at US$ 8.09 billion.
Until 2033, the market will experience a 6.51% CAGR.
Advancements in treatments and therapies drive market growth.
Organic onions will expand at a 7% CAGR through 2033.
Orpha Labs, Avalo Therapeutics, Inc., and Rocket Pharmaceuticals Inc., are some key players.
1. Executive Summary | Leukocyte Adhesion Deficiency Management Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Hematopoietic Stem Cell Transplantation 5.2. Recombinant Human Interferon-gamma Treatment 5.3. Prophylactic Immunoglobulin Therapy 5.4. Antimicrobial Therapy 5.5. Prophylactic Therapy 5.6. Fucose Supplementation 5.7. Monoclonal Antibodies 5.8. Coagulation Factors 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users 6.1. Hospitals 6.2. Specialty Clinics 6.3. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. Middle East and Africa 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. Orpha Labs 15.2. Avalo Therapeutics, Inc. 15.3. Rocket Pharmaceuticals Inc. 15.4. Sigma-Aldrich 15.5. Aspen Neuroscience 15.6. Magenta Therapeutics 15.7. Rubius Therapeutics 15.8. Enochian Biosciences 15.9. Sana Biotechnology 15.10. Vertex Pharmaceuticals 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Leukocyte Adhesion Deficiency Management Market
